Coronavirus

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub

Moderna’s covid-19 patent pledge may be backfiring
Ranking as Asia’s most innovative economy highlights South Korea’s need for IP value creation
27 Sep 2021

Ranking as Asia’s most innovative economy highlights South Korea’s need for IP value creation

World-beating R&D and patent rates propel country to top of Asia for the first time in annual WIPO study, but Global Innovation Index also shows areas where IP professionals can help it improve further

Moderna’s covid-19 IP pledge is about to be put to the test
24 Sep 2021

Moderna’s covid-19 IP pledge is about to be put to the test

The WHO’s African vaccine hub is seeking to imitate the company’s jab, but an agreement has yet to be reached

Latest

View all
9 Sep 2021

Life science leaders

Read more

3 Sep 2021

Bolsonaro vetoes Brazil’s first-of-a-kind compulsory tech transfer law

The president’s rejection of forced know-how licensing will now be reviewed by the country’s Congress, but a new patent suspension regime is set to come into force Read more

19 Aug 2021

Brazil on the cusp of passing landmark compulsory technology transfer law

Life sciences innovators may be compelled to hand over trade secrets, data and biological materials under legislation that now only requires President Bolsonaro’s signature to become law Read more

12 Aug 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field Read more

News

View all
8 May 2021

Biden’s backing for the covid vaccine IP waiver should concern all rights owners

This week’s unprecedented move raises a series of worrying questions and puts in doubt the administration’s commitment to fostering innovative activity Read more

26 Apr 2021

Get smarter about covid patents or pay the price

On World IP Day it's time to get a few things straight about where the real problems in getting jabs to those who need them really lie Read more

2 Mar 2021

Negotiating patent licensing agreements during a pandemic

Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

Analysis

View all
17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

28 May 2021

The Medicines Patent Pool – not C-TAP – is the missed opportunity for covid vaccines

A scheme premised on a rejection of the legitimacy of IP during a pandemic was never going to get the buy-in necessary to make it work Read more

25 May 2021

The USPTO Director choice may effectively come down to Chris Coons

White House backing for the covid vaccine IP waiver puts the pro-patent Delaware senator in a powerful position to decide who gets the job Read more

21 May 2021

As the pandemic bit, Schaeffler Group, Sanofi and Abbott led the way with US patent abandonments in 2020

Exclusive IAM analysis reveals how leading businesses in seven industries handled renewals at the height of the covid-19 crisis Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more